Form 4: Plus Therapeutics Director Acquires Stock Options

Director Howard Clowes of Plus Therapeutics, Inc. acquired stock options and restricted stock units, indicating continued commitment and potential future equity.

Summary

• Howard Clowes, a Director at Plus Therapeutics, Inc., acquired 3,686 Restricted Stock Units (RSUs) and 3,686 stock options on May 14, 2026.
• The RSUs vest ratably over four quarters, with the first 1/4 vesting on July 1, 2026, and the remainder vesting quarterly thereafter.
• The stock options vest monthly over 12 months from the grant date, with full vesting contingent on continued service or the Issuer's 2027 Annual Stockholder Meeting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects a director's continued engagement and potential future stake in the company through equity awards, but it does not represent new financial performance data.

Positives

• Director Howard Clowes has acquired equity awards, suggesting confidence in the company's future prospects.
• The acquisition of both RSUs and stock options provides potential upside for the director.
• Vesting schedules are clearly defined, aligning with continued service and company milestones.

Risks

• The value of the RSUs and stock options is contingent on the future performance of Plus Therapeutics' stock price.
• Vesting is subject to continued service, meaning forfeiture is possible if the director leaves the company before vesting dates.
• The stock options have an exercise price of $5.76, meaning they will only be profitable if the stock price exceeds this level.

Future Outlook

The vesting schedules for RSUs and stock options indicate a forward-looking incentive structure tied to continued service and company performance, with options potentially vesting fully by the 2027 Annual Stockholder Meeting.

Industry Context

StockSavvy.ai notes that the acquisition of equity awards by a director is a common practice in the biotechnology and pharmaceutical sectors, often used to align executive interests with shareholder value and incentivize long-term commitment.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director may be viewed positively, signaling confidence, but the direct financial impact is contingent on future stock performance.
• Employees: The vesting schedules for the director's awards may indirectly influence employee compensation strategies and retention efforts.
• Management: Reinforces the alignment of management's interests with those of shareholders through equity ownership.

Next Steps

• Vesting of Restricted Stock Units commencing July 1, 2026, and continuing quarterly.
• Monthly vesting of stock options over 12 months from the grant date.
• Potential full vesting of stock options by the Issuer's 2027 Annual Stockholder Meeting.

Key Dates

Keywords

Plus Therapeutics, PSTV, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Awards, SEC Filing